The susceptibility of various strains of Cryptococcus neoformans to killing by human polymorphonuclear leukocytes (PMNs) Cryptococcus neoformans is a significant cause of opportunistic infection in patients with impaired cellular immunity (26, 28). Cryptococcal meningitis occurs more frequently in patients who have received corticosteroids, patients with hematological malignancies, and patients with AIDS, in whom the incidence of cryptococcosis is estimated at 10 to 15% (14, 17, 26).
The susceptibility of various strains of Cryptococcus neoformans to killing by human polymorphonuclear leukocytes (PMNs) and monocytes was investigated. Five previously characterized strains of C. neoformans serotype A, a capsule-free mutant, and six recent clinical isolates were compared. PMNs and monocytes were isolated from normal peripheral blood and allowed to adhere to the flat-bottom wells of microtiter plates. Yeast cells of C. neoformans were added in the presence of normal human serum, and the plates were incubated at 37°C. After 12 strains, PMNs killed C. neoformans more effectively than did monocytes. Significant interstrain variation in killing occurred for both monocytes and PMNs, and the recent, clinical isolates were more resistant to killing by monocytes and PMNs than were the previously characterized strains. The extent to which different strains were killed by monocytes and PMNs was not consistently related to the size of the capsule or the entire cell. Normal PMNs and monocytes are remarkably effective in killing strains of C. neoformans in the absence of specific antibody and appear to constitute a significant defense mechanism in the peripheral circulation.
Cryptococcus neoformans is a significant cause of opportunistic infection in patients with impaired cellular immunity (26, 28) . Cryptococcal meningitis occurs more frequently in patients who have received corticosteroids, patients with hematological malignancies, and patients with AIDS, in whom the incidence of cryptococcosis is estimated at 10 to 15% (14, 17, 26) .
Clinical and experimental evidence indicates that the initial pulmonary defenses against cryptococcosis involve the responses of T cells and the activities of alveolar macrophages (4, 5, 10, 11, 25, 26, 38) . Recent murine studies suggest that natural killer cells may contribute to natural immunity against yeast cells (31, 32) , but human natural killer cells are ineffective against C. neoformans in the absence of antibody (27) . Therefore, in the peripiheral blood, polymorphonuclear leukocytes or neutrophils (PMNs) and monocytes are the likely crucial defenses against cryptococcemia.
Phagocytosis of C. neoformans by PMNs and monocytes is promoted by complement. Activation of complement and deposition of C3 usually occurs by the alternative complement pathway, since specific anticryptococcal antibody is rarely present in patients with cryptococcosis (13, 15, 16, 23) . Killing of C. neoformans by phagocytes may occur intracellularly (13) or extracellularly (38) . Several studies have explored the mechanism of phagocytosis of C. neoformans by granulocytes and monocytes (9, 20, 21, 23) , but only one study has carefully examined the killing of these yeast cells by peripheral leukocytes in the absence of specific antibody (13) . (4, 5) , and (iii) the relative molecular sizes, compositions, and binding capacities of the capsular polysaccharides (34, 36) . Strain 602, a capsule-free mutant, was a gift from Thomas R. Kozel (18) . As described in a previous report (27) (27) .
Isolation of human PMNs and monocytes. Venous blood from healthy human donors was collected in heparin (20 U/ml) and subsequently mixed with an equal volume of 3% dextran (Sigma, St. Louis, Mo.) in 0.85% NaCl. The cells were allowed to sediment by gravity for 45 min; the supernatant was layered onto a discontinuous gradient of FicollHypaque (LSM; Organon Teknica, Durham, N.C.) and centrifuged at 400 x g for 30 min. The cells at the resulting interface were removed, washed, and resuspended in medium composed of RPMI 1640 (GIBCO, Grand Island, N.Y.) supplemented with L-glutamine, 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer, penicillin (100 U/ml), and streptomycin (100 ,ug/ml) (RPMI). To recover monocytes, the cell suspension was incubated in petri dishes at 37°C under 5% C02-95% air for 60 min. The nonadherent cells were discarded, and the plates were rinsed several times with warm phosphate-buffered saline, pH 7.4. The adherent cells were mechanically removed with a rubber policeman. Viability, as determined with trypan blue, ranged between 80 and 90%, and >95% of the cells were monocytic in appearance. The cells were resuspended at 3 x 106 viable monocytes per ml in RPMI with 10% (vol/vol) heat-inactivated fetal calf serum (GIBCO) (RPMI-FCS). The remaining supernatant from the Ficoll-Hypaque separation was discarded, the pellet was resuspended, and the erythrocytes were lysed by trituration with 0.1% NaCl, after which 1.7% NaCl was added to restore isotonicity. This suspension was centrifuged for 15 min at 260 x g, the supernatant was discarded, and the PMNs were resuspended in RPMI-FCS. Both purity and viability were >98%, as determined by trypan blue, and the PMNs were adjusted to 3 x 106 viable cells per ml.
Killing of C. neoformans by PMNs and monocytes. Killing of C. neoformans was evaluated by comparing the percentage of viable yeast cells incubated in the presence of effector cells (PMNs or monocytes) with control growth in the absence of effectors. The viable yeast census was determined with a quantitative pour plate assay as described previously (27) . After growth for 3 days on GYE slants at 37°C, yeast cells of C. neoformans were harvested, counted in a hemacytometer chamber, and diluted in RPMI. One hundred microliters of effector cells at 3 x 106 viable cells per ml was added to the flat-bottom wells of microtiter plates (no. 3596; Costar, Cambridge, Mass.). The plates were incubated at 37°C under 5% CO2 for 60 min, and the medium was removed and replaced with 100 RI of RPMI with 10% normal human serum, which was collected from healthy volunteers with blood type AB. Yeast cells were harvested as described above and suspended in RPMI at 3 x 105 CFU/ml. Samples of 10 or 20 ,ul of this suspension were added to appropriate wells to yield effector-to-yeast target (E:T) ratios of 100:1 and 50:1, respectively. An E:T ratio of 1:1 was achieved by adding 100 RI of yeast cells at 3 x 106 CFU/ml of RPMI-normal human serum. After incubation at 37°C in 5% CO2 for 4 h, 100 ,ul of 0.25% (vol/vol) Triton X-100 was added to all wells to lyse the monocytes or PMNs and release phagocytized yeast cells, and the plates were reincubated for 15 min. The wells were washed three times with sterile water, the washes were pooled and serially diluted, and portions of the final dilution (200 ,u to 1.0 ml)
were placed in sterile petri plates. Molten GYE at 480C was poured over the samples; the plates were mixed, allowed to solidify, and incubated at 37°C for 3 days; and the colonies were counted. Growth at each E:T ratio was assessed in triplicate and compared with growth of corresponding control wells containing only yeast cells in RPMI-normal human serum. Microscopic examination of wells and wash fluids revealed that the monocytes and PMNs were completely lysed by Triton X-100, and preliminary experiments confirmed that under these conditions Triton X-100 had no effect on the clumping of the yeast cells or determination of the viable CFU per milliliter. Residual leukocyte fragments were not visible in the wells or the wash fluids. Viability of the effector cells, as determined by the exclusion of trypan blue, was >95% after 4 h in the presence or absence of yeast cells.
After 3 days of incubation at 37°C, the CFU of C. neoformans were enumerated and the percentage of killing was calculated as follows: (1 -mean experimental CFU/ mean control CFU) x 100. The mean CFU of each experimental and control value was calculated from six plates, three plates of a relatively low dilution that usually resulted in 80 to 180 CFU per plate and triplicate plates of a higher dilution usually yielding 25 to 80 CFU per plate. The mean CFU of each triplicate was multiplied by the dilution factor, and the average of the two computations produced the final mean CFU per milliliter. The standard deviation for each mean rarely exceeded 10% and was always less than 15%.
PMNs and monocytes from different human donors may vary in their abilities to kill C. neoformans (13) . All of the data in this investigation were derived from leukocytes that were obtained from a total of three donors. Each strain of C.
neoformans was evaluated in three to eight experiments, and two to six strains were compared in each experiment.
Statistical analysis. The Student t test for paired means was applied to compare PMN and monocyte growth inhibition data. The experimental mean was compared with the control mean for each experiment. Linear regression analysis was used to correlate the killing data with yeast capsule size and particle diameter.
RESULTS
Since variations in the growth rates of the different strains of C. neoformans could affect the assays of killing, growth curves were generated for most of the strains, and the doubling times were calculated during logarithmic growth. In either buffered glutamine-glycine-asparagine (36) medium or RPMI-FCS, the mean doubling time and standard deviation was 5.93 ± 0.68 h and ranged from 5.2 to 7.0 h (27) Tables 1 and 2 , respectively. Both PMNs and monocytes significantly killed (P < 0.005) all of the encapsulated strains of C. neoformans at all three E:T ratios. The percentages of killing of the encapsulated strains were consistently >75% for both effector leukocytes at E:T ratios of 100:1 and 50:1. At the ratio of 1:1, killing by PMNs varied from 33.5 to 88% (Table 1) , and monocytes killed 14.5 to 63.5% of the yeast cells ( Table 2 ). The capsule-free strain 602 was more susceptible than the (Table 1 ) and more resistant to monocytes ( Table 2 ). PMNs were generally more effective than monocytes in killing the encapsulated strains. Since none of the strains multiplied appreciably during the 4 h of incubation in control wells containing medium without leukocytes, any difference between experimental and con- Killing of these encapsulated strains by PMNs at the E:T ratio of 1:1 (Table 1) was inversely related to both capsule width and particle diameter (i.e., cell diameter plus twice the capsule width) (27) . The respective linear regression coefficients for these relationships were 0.97 and 0.95. A similar but less striking correlation existed between killing by monocytes at the 1:1 ratio and dimensions of the capsule and particle.
Six recent clinical isolates were also tested against PMNs and monocytes. These strains varied according to the specimen from which they were isolated, the underlying disease of the patient, and the capsule and cell sizes (27) . To discern any differences in susceptibility to PMNs or monocytes, only E:T ratios of 1:1 were tested since higher ratios were effective against C. neoformans. Although the strains varied in susceptibility (Table 3) , both PMNs and monocytes killed these strains quite effectively (P < 0.001, compared with controls). Strain variation in susceptibility to killing was apparent. At the same ratio, the recently isolated strains Table 1 for explanation of capsule widths, particle sizes, and percent killing by PMNs and monocytes. E:T ratio is 1:1; P < 0.001 for all values, comparing mean experimental with control CFU.
were significantly more resistance (P < 0.01) to PMNs and monocytes than were the previously characterized strains of comparable capsule and particle size (Table 3 versus Tables  1 and 2 ). Reproducible strain differences in killing by monocytes were observed. PMNs were more effective than monocytes in killing three of the strains (1458, 1988, and 1508), but killing was comparable against the other three strains (1218, 1188, and 1948). As found previously, no appreciable growth of these strains occurred during the period of incubation. Strains 1508, 1188, and 1948 were obtained from patients with AIDS (27) . No correlation was found between PMN or monocyte killing and capsule or particle size of these clinical isolates.
DISCUSSION
Human PMNs and monocytes, in the presence of normal human serum, efficiently killed strains of C. neoformans at E:T ratios as low as 1:1. Killing of C. neoformans by phagocytes occurs both intracellularly and extracellularly (13) . This investigation did not distinguish between intracellular and extracellular killing. Phagocytosis is mediated by activation by the alternative complement pathway and opsonization of the yeast cell (9, 20, 23) . C3b and iC3b are concentrated at the periphery of the capsule, facilitating interaction with phagocytic complement receptors (21, 22) . Anticryptococcal antibody was not used in this study as an opsonin since anticapsular immunoglobulin G does not increase granulocyte or monocyte phagocytosis or killing capacity (9, 13, 20) .
Considerable strain variation in susceptibility to killing was observed among the 12 strains of C. neoformans that were tested against PMNs and monocytes. The range of percent killing by both PMNs and monocytes was consistent with reports of killing by human peripheral leukocytes (13) . Nine of the strains were killed more efficiently by PMNs than monocytes. Diamond et al. (13) reported that PMNs were more effective than monocytes in killing both strains of C. neoformans that they studied. Kozel et al. (20) showed that PMNs were superior to monocytes in phagocytizing the yeasts in the presence of C3 or rabbit anticapsular immunoglobulin G.
Comparison of strains of similar capsule and particle sizes showed that the recent isolates were more resistant to killing by both PMNs and monocytes than were the previously studied laboratory strains. This increased resistance may indicate that maintenance for long periods selects less resistant cells. To test this hypothesis, inbred animals will be used to compare the virulence and phagocytosis of these strains. Isolates from patients with AIDS were reported to have smaller capsule and cell sizes (6, 7) , but in this study, the three strains from AIDS patients ( The capsular polysaccharide of C. neoformans is associated with virulence and possesses a number of pathobiological properties, including specific inhibition of phagocytosis (8, 22, 35) and suppression of both antibody production and cell-mediated immune responses (2, 3, 19, 29, 30) .
The capsule may impede phagocytosis by preventing adequate contact between phagocytic receptors and opsonins or ligands on the cell surface (24) . To determine whether capsule width or whole particle size (cell size plus twice the capsule width) correlated with killing by PMNs or monocytes, both the capsule width and cell size were measured (Tables 1 and 3) . Killing of the five previously characterized, encapsulated strains by either PMNs or monocytes was somewhat inversely correlated with both capsule and particle sizes. This relationship was more apparent at the E:T ratio of 1:1. Strains 145, 98, and 110 were relatively similar is size and comparably killed by PMNs, whereas the largest strain, strain 6, was more resistant and the smallest, strain 15, was killed most effectively (Table 1) . This pattern was similar with monocytes ( Table 2 ). The relative influence of capsule size versus particle size could not be differentiated.
With rat alveolar macrophages, strain variation in susceptibility to phagocytosis is inversely related to capsule size, but the amount of killing is unrelated to either capsule size or the extent of phagocytosis (4, 5) . The patterns of killing of these strains were not entirely consistent. At 1:1 ratios, strains 98 and 145 were relatively susceptible to killing by both human monocytes and rat alveolar macrophages. However, strain 110 was the most resistant to rat alveolar macrophages (5) , and strain 6 was the most resistant to human PMNs and monocytes (Tables 1 and 2 ). The capsulefree strain 602 was killed most effectively by PMNs but less efficiently by monocytes than were the encapsulated strains, which is consistent with the recently reported resistance of capsule-free cells to alveolar macrophages (25) .
Among the recent clinical isolates, killing by both PMNs and monocytes was pronounced (Table 3) . However, the variation among strains in susceptibility to killing did not correlate with capsule or particle size. Strain variation in killing may also provide a tool to study the differing mechanisms of killing among PMNs, monocytes, and macrophages. Resistance to killing is a likely determinant of the pathogenicity of a strain.
PMNs and monocytes represent effective host defenses against both poorly and highly encapsulated yeast cells of C. neoformans. Yeasts that are not killed within the lung, or elsewhere, may enter the circulation. (A frequent risk factor associated with cryptococcemia is the administration of corticosteroids [33] .) These nonspecific effector cells undoubtedly provide superior defense against invasion of the bloodstream, as natural killer cells were ineffective in vitro (27) . Although PMNs are not a common feature in cryptococcal lesions, and patients with neutropenia are not at particular risk for cryptococcosis, patients receiving immunosuppressive therapy and patients with AIDS are more susceptible to cryptococcosis and often have phagocytic and chemotactic defects of their neutrophils and monocytes (1, 12) . However, in autologous serum, monocytes from patients with AIDS were able to kill a strain of C. neoformans (37 
